The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

Bibliography

• Chiu BC, Hou N. Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treat Res 2015;165:1-25
   PubMedGoogle Scholar
• Cohen JB, Flowers CR. Optimal disease surveillance strategies in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2014;2014:481-7
   PubMed Web of Science ®Google Scholar
• Skrabek P, Turner D, Seftel M. Epidemiology of non-Hodgkin lymphoma. Transfus Apher Sci 2013;49:133-8
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Bernstein ID, Tam MR, Nowinski RC. Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science 1980;207:68-71
   PubMed Web of Science ®Google Scholar
• Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980;40:3147-54
   PubMed Web of Science ®Google Scholar
• Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517-22
   PubMed Web of Science ®Google Scholar
• Clark EA, Shu G, Ledbetter JA. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA 1985;82:1766-70
   PubMed Web of Science ®Google Scholar
• Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91
   PubMed Web of Science ®Google Scholar
• Liu AY, Robinson RR, Murray EDJr, et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987;139:3521-6
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269-77
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42
   PubMed Web of Science ®Google Scholar
• Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol 2003;123(5):850-7
   PubMed Web of Science ®Google Scholar
• Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008;3:1157-71
   PubMedGoogle Scholar
• Maloney DG, Grillo-López AJ, White CA, et al. DEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139:439-46
   PubMed Web of Science ®Google Scholar
• Kotani N, Ishiura Y, Yamashita R, et al. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. J Biol Chem 2012;287:37109-18
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Buhl AM, Klausen P, et al. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99:1314-19
   PubMed Web of Science ®Google Scholar
• Grillo-López AJ. Rituximab: an insider’s historical perspective. Semin Oncol 2000;27(6 Suppl 12):9-16
   PubMed Web of Science ®Google Scholar
• Levy R. A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol 2000;37(4 Suppl 7):43-6
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23
   PubMed Web of Science ®Google Scholar
• Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituximab: modes of action, remaining dispute and future perspective. Future Oncol 2014;10:2481-92
   PubMed Web of Science ®Google Scholar
• Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30(1 Suppl 2):3-8
   PubMed Web of Science ®Google Scholar
• Nishida M, Usuda S, Okabe M, et al. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 2007;31:29-40
   Google Scholar
• Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24
   PubMed Web of Science ®Google Scholar
• LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-86
   PubMed Web of Science ®Google Scholar
• McLaughlin P, White CA, Grillo-López AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 1998;12:1763-9
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Xiu Y, Komura K, et al. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006;203:743-53
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008;112:1205-13
   PubMed Web of Science ®Google Scholar
• Boross P, Jansen JH, de Haij S, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011;96:1822-30
   Google Scholar
• Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48 L/R/H phenotype. Blood 1997;90:1109-14
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7
   PubMed Web of Science ®Google Scholar
• Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8
   PubMed Web of Science ®Google Scholar
• Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010;116:4212-22
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Cartron G, Seymour JF, et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012;120:2650-7
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Jazirehi AR, Bonavida B, Rituximab-Mediated Sensitization of B-Non-Hodgkin’s Lymphoma (NHL) to Cytotoxicity Induced by paclitaxel, pemcitabine, and vinorelbine. Cancer Biotherapy and Radiopharmaceuticals 2002;17:621-60
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Gan XH, De Vos S, et al. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin’s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003;2:1183-93
   PubMed Web of Science ®Google Scholar
• Van der Kolk, Evers LM, Omene C, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002;16:1735-44
   PubMed Web of Science ®Google Scholar
• Vega MI, Huerta-Yepez S, Jazirehi AR, et al. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005;24:8114-27
   PubMed Web of Science ®Google Scholar
• Eeva J, Nuutinen U, Ropponen A, et al. The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells. Apoptosis 2009;14:687-98
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673-83
   PubMed Web of Science ®Google Scholar
• Al-Zoobi L, Salti S, Colavecchio A, et al. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface. Int Immunol 2014;26:451-65
   PubMed Web of Science ®Google Scholar
• Daniels I, Abulayha AM, Thomson BJ, Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006;11:1013-23
   PubMedGoogle Scholar
• Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961-6
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143-59
   PubMed Web of Science ®Google Scholar
• Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002;100:1765-73
   PubMed Web of Science ®Google Scholar
• Furlan A, Villanova F, Pietrogrande F, et al. Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro. Leuk Lymphoma 2010;51:107-13
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87:33-43
   PubMed Web of Science ®Google Scholar
• Deyab M, Elbanani A, Tabal S, et al. Rituximab synergizes with hydroxyurea or vincristine in the killing of Ramos Burkitt’s lymphoma B cell line. Cancer Biother Radiopharm 2014;29:87-90
   PubMed Web of Science ®Google Scholar
• Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008;22:179-85
   PubMed Web of Science ®Google Scholar
• Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol 2013;162:657-69
   PubMed Web of Science ®Google Scholar
• Gu JJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models. Anticancer Drugs 2013;24:1030-8
   PubMed Web of Science ®Google Scholar
• Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin’s lymphoma cell lines in vitro and in scid mice. BMC Cancer 2005;5:103
   PubMed Web of Science ®Google Scholar
• Xu ZZ, Wang WF, Fu WB, et al. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma. Leuk Lymphoma 2014;55:1151-7
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008;111:5350-8
   PubMed Web of Science ®Google Scholar
• Smith MR, Joshi J. Fang Jin. Enhanced efficacy of therapy with antisense Bcl-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid/human lymphoma xenografts. Mol Cancer Ther 2004;3:1693-9
   PubMed Web of Science ®Google Scholar
• Majchrzak A, Witkowska M, Mędra A, et al. In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line. Postepy Hig Med Dosw 2013;67:1166-72
   Web of Science ®Google Scholar
• Smolewski P, Witkowska M, Zwolinska M, et al. Cytotoxic activity of the amphibian ribonucleases onconase and r-amphinase on tumor cells from B cell lymphoproliferative disorders. Int J Oncol 2014;45:419-25
   PubMed Web of Science ®Google Scholar
• Dijoseph JF, Dougher MM, Armellino DC, et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother 2007;56:1107-17
   PubMed Web of Science ®Google Scholar
• Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005;46:87-100
   PubMed Web of Science ®Google Scholar
• Alinari L, Yu B, Christian BA, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011;117:4530-41
   PubMed Web of Science ®Google Scholar
• Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol 2014;S0161-5890(14):00259-4
   Google Scholar
• Van Den Neste E, Van den Berghe G, Bontemps F. AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opin Investig Drugs 2010;19:571-8
   PubMed Web of Science ®Google Scholar
• Montraveta A, Xargay-Torrent S, López-Guerra M, et al. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget 2014;5:726-39
   PubMedGoogle Scholar
• Duong MN, Matera EL, Mathé D, et al. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. MAbs 2015;7:192-8
   PubMed Web of Science ®Google Scholar
• Roit FD, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015;100:77-86
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10
   PubMed Web of Science ®Google Scholar
• Ziolkowska E, Wolowiec D, Cebula-Obrzut B, et al. Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. Postepy Hig Med Dosw 2014;68:1433-43
   Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res 2008;14:4650-7
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45
   PubMed Web of Science ®Google Scholar
• Berg SL, Cairo MS, Russell H, et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a children’s oncology group Phase I consortium report. J Clin Oncol 2011;29:316-23
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128(2):192-203
   PubMed Web of Science ®Google Scholar
• Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int 2014;2014:265840
   PubMed Web of Science ®Google Scholar
• Fowler N, Hagemeister F, Mclaughlin P, et al. High response rates with lenalidomide plus rituximab for untreated indolent B cell non-Hodgkins lymphoma. Ann Oncol 2011;22(Suppl 4):iv128-9
   Google Scholar
• Hainsworth JD, Litchy S, Burris HAIII, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J. Clin. Oncol 2002;20:4261-7
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J. Clin. Oncol 2009;27:5404-9
   PubMed Web of Science ®Google Scholar
• Evens AM, Spies WG, Helenowski IB, et al. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin’s lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res 2009;15:6462-71
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013;163:393-9
   PubMed Web of Science ®Google Scholar
• Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013;121:1976-81
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schmitz N, Gisselbrecht C, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2013;31:1624-30
   PubMed Web of Science ®Google Scholar
• Al-Zoobi L, Salti S, Colavecchio A, et al. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. Am J Hematol 2015;90:230-4
   PubMed Web of Science ®Google Scholar
• van den Hoogen MW, Kamburova EG, Baas MC, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 2015;15:407-16
   PubMed Web of Science ®Google Scholar
• Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation 2014;98:794-805
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Balighi K, Daneshpazhooh M, Khezri S, et al. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol 2013;52:862-7
   PubMed Web of Science ®Google Scholar
• Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013; update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28
   Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014;15:343-52
   PubMed Web of Science ®Google Scholar
• St Clair EW, Levesque MC, Prak ET, et al. Autoimmunity Centers of Excellence. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013;65:1097-106
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Harrison AM, Thalji NM, Greenberg AJ, et al. Rituximab for non-Hodgkin’s lymphoma: a story of rapid success in translation. Clin Transl Sci 2014;7:82-6
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Montserrat E. Rituximab in chronic lymphocytic Leukemia. Semin Oncol 2003;30(1 Suppl 2):34-9
   PubMed Web of Science ®Google Scholar
• Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 2014;89:429-3673B
   PubMed Web of Science ®Google Scholar
• Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res 2010;16:2435-42
   PubMed Web of Science ®Google Scholar
• Winter JN, Li S, Aurora V, et al.et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res 2010;16:2435-42
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013-22
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525-33
   PubMed Web of Science ®Google Scholar
• Molina TJ, Canioni D, Copie-Bergman C, et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d’Etudes des Lymphomes de l’Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol 2014;32:3996-4003
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-95
   PubMed Web of Science ®Google Scholar
• Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014;15:730-7
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Foá R, Di Rocco A, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol 2014;93:1717-24
   PubMed Web of Science ®Google Scholar
• Chang JE, Li H, Smith MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood 2014;123:1665-73
   PubMed Web of Science ®Google Scholar
• Foà R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014;89:480-6
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014;15:424-35
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416-23
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Br J Haematol 2010;115:489-95
   Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15:090-9
   Web of Science ®Google Scholar
• Seymour JF, Pfreundschuh M, Trněný M, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica 2014;99:1343-9
   PubMed Web of Science ®Google Scholar
• Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013;98:1726-31
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-26
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:1250-9
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 2012;12:503-15
   PubMed Web of Science ®Google Scholar
• Robak T. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Rev Hematol 2014;7:841-57
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter WF, Hourcade-Potelleret F, et al. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg) 2014;6411:569-75
   Google Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol 2014;32:1782-91
   PubMed Web of Science ®Google Scholar
• Bremer K. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non Hodgkin’s lymphoma: a phase II study. Anti-Cancer Drugs 2003;14:809-15
   PubMedGoogle Scholar
• Aviles A, Leon MI, Diaz-Maqueo JC, et al. Rituximab in the treatment of refractory follicular lymphoma–six doses are better than four. J Hematother Stem Cell Res 2001;10:313-16
   PubMed Web of Science ®Google Scholar
• Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999;10:655-61
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70
   PubMed Web of Science ®Google Scholar
• Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002;13:928-43
   PubMed Web of Science ®Google Scholar
• Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096-102
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behaviour of rituximab. A study of different schedules of administration for heterogenous clinical settings. Ther Drug Monit 2005;27:785-92
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with standard weekly X4 schedule. Blood 2004;103:4416-23
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:4261-7
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301
   PubMed Web of Science ®Google Scholar
• Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokinetic–pharmacodynamic modeling–a new classification of biomarkers. Pharm Res 2005;22:1432-7
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, et al. Radioimmunoconjugates for the treatment of cancer. Semin Oncol 2014;41:613-22
   PubMed Web of Science ®Google Scholar
• Arnason JE, Luptakova K, Rosenblatt J, et al. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematol 2015;13:347-
   Web of Science ®Google Scholar
• Ibatici A, Pica GM, Nati S, et al. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol 2014;164:710-16
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol 2013;31:1977-83
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55
   PubMed Web of Science ®Google Scholar
• Baig NA, Taylor RP, Lindorfer MA, et al. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma 2012;53:2218-27
   PubMed Web of Science ®Google Scholar
• Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012;156:490-8
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin Cancer Res 2004;10:2868-78
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51:747-55
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs 2015;7:1-8
   PubMed Web of Science ®Google Scholar
• Cheney CM, Stephens DM, Mo X, et al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 2014;6:749-55
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, de Vos S, Pohlman BL, et al. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. Leuk Lymphoma 2015;56:42–8
   PubMed Web of Science ®Google Scholar
• Kahl BS, Cheson BD, Friedberg JW. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol 2010;8:1-16
   PubMedGoogle Scholar
• Casulo C, Vose JM, Ho WY, et al. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. Clin Immunol 2014;154:37-46
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 2011;108:12669-74
   PubMed Web of Science ®Google Scholar
• Illidge TM. Obinutuzumab (GA101)-a different anti-CD20 antibody with great expectations. Expert Opin Biol Ther 2012;12:543-5
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013;12:2031-42
   PubMed Web of Science ®Google Scholar
• Hoy SM. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia. Drugs 2015;75:285-96
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015;10.1038/leu.2015.14
   PubMed Web of Science ®Google Scholar
• Middleton O, Cosimo E, Dobbin E, et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 2015;29:107-14
   PubMed Web of Science ®Google Scholar
• Yu B, Mao Y, Yuan Y, et al. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials 2013;34:6185-93
   PubMed Web of Science ®Google Scholar
• Raufi A, Ebrahim AS, Al-Katib A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res 2013;5:225-33
   PubMedGoogle Scholar
• Alinari L, Quinion C, Blum K. Bruton’s tyrosine kinase inhibitors in B-cell non-Hodgkin’s lymphomas. Clin Pharmacol Ther 2015;10.1002/cpt.65. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Keating GM. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma. Target Oncol 2015. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bojarczuk K, Siernicka M, Dwojak M, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 2014;28:1163-7
   PubMed Web of Science ®Google Scholar